Navigation Links
Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:12/17/2008

SAN FRANCISCO, Dec. 17 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it has completed patient enrollment in a Phase 1-2 dose-escalation clinical trial of MDV3100, its novel androgen receptor antagonist, in castration-resistant prostate cancer patients, and that it will seek approval from the U.S. Food and Drug Administration (FDA) to advance to Phase 3 clinical trials next year.

The open-label, U.S. Phase 1-2 study evaluated prostate cancer patients who had failed standard hormonal therapies, including men who had also failed standard chemotherapy regimens. A total of 140 men were enrolled in the trial, which evaluated doses between 30 and 600 mg/day. Patients are being followed and may remain on treatment for as long as they continue to tolerate the drug and their disease does not progress.

Preliminary results of this trial, covering 73 treated patients in the 60, 150 and 240 mg/day dose groups, were presented in October at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The data showed encouraging and durable anti-tumor activity as measured by prostate specific antigen (PSA) declines, radiographic findings, circulating tumor cell (CTC) changes and time on treatment. These data also suggested a dose-response trend, with a higher percentage of patients in the 240 mg/day dose group experiencing 90 percent reduction in PSA levels, radiographic partial responses and conversions to favorable CTC counts of less than five post-treatment.

The Company expects to move into Phase 3 trials with either the 240 or the 360 mg/day dose, both of which have been generally well tolerated. The 480 mg/day dose did not have acceptable tolerability due to side effects, primarily fatigue. Efficacy data from the 360 mg/day dose group are under analysis and wil
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 According to ... & Intravascular Systems- Warming & Cooling), Application (Acute ... & Anesthesiologist, Nursing & Paramedical Staff) - Global ... report studies the global Temperature Management Market over ... market is expected to reach $2.5 Billion by ...
(Date:9/18/2014)... 18, 2014 This BCC Research report discusses the medical ... market growth and size, and opportunities for different devices and ... 2018. Patent analysis in the report focuses on technological trends ... Europe and Japan . ... discuss the global medical device technologies market. - Analyze market ...
(Date:9/18/2014)... FRANCISCO , Sept. 18, 2014   Fruit ... has secured an initial seed round of funding. ... investments, was led by a series of individual investors, ... investors whom participated in the initial round are; ... Valley Medical Center Urologist Stacy Childs, Rapha Family Medicine ...
Breaking Medicine Technology:Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3
... SynCardia Systems, Inc. ( www.syncardia.com ), manufacturer of ... CE (Europe) approved Total Artificial Heart, announced record-setting revenue ... part to Certified Centers performing a record number of ... . (Photo: http://photos.prnewswire.com/prnh/20120517/LA08709 ) ...
... 17, 2012  SuccessEHS, a nationally recognized electronic ... software vendor, kicked off its annual Customer ... Birmingham. SuccessEHS selected "Forward Together" as ... commitment to helping its clients successfully navigate the ...
Cached Medicine Technology:SynCardia Posts Record Revenue and Profit in Q1 2012 2SynCardia Posts Record Revenue and Profit in Q1 2012 3SuccessEHS "Forward Together" Customer Conference Begins 2SuccessEHS "Forward Together" Customer Conference Begins 3
(Date:9/18/2014)... (PRWEB) September 18, 2014 Companies in ... refine carbon dioxide, selling it to downstream industries in ... for carbon dioxide are food and beverage manufacturers. Food ... as fruits, vegetables or pizzas. The gas is also ... use the compound to carbonate soft drinks, beer and ...
(Date:9/18/2014)... Amy Norton HealthDay Reporter , ... dose of a common antidepressant can quickly alter the way ... The findings, reported online Sept. 18 in Current ... response to widely prescribed antidepressants. Experts said the hope is ... are likely to benefit from a drug -- and which ...
(Date:9/18/2014)... (CHEST) together with the Chinese Thoracic Society (CTS) ... that CHEST World Congress 2016 will be held ... and sleep medicine from around the world are ... spring 2016. , CHEST World Congress 2016 ... training, keynote addresses, presentations by leading health-care experts, ...
(Date:9/18/2014)... City, UT (PRWEB) September 18, 2014 ... America will be recognizing their shared fundraising impact on ... Thursday, Sept. 25. , The first-ever Dance Marathon Day ... than $20 million projected to be raised by college ... community’s CMN Hospital. Donations generated through Dance Marathon campus ...
(Date:9/18/2014)... Baltimore, MD (PRWEB) September 18, 2014 ... Award-winning celebrity and wellness advocate, and Frank Davis, ... Activz Whole-food Nutrition, are pleased to announce ... 150+ ways to make delicious, nutrition-packed meals using ... book is the next step in the ...
Breaking Medicine News(10 mins):Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3
... Miguel ngel Fullana, researcher at the Universitat Autnoma ... psychologist the Institute of Psychiatric Treatment of Hospital ... College Institute of Psychiatry, London, has carried out ... obsessive-compulsive rituals in childhood with the risk of ...
... March 4 Beginning February 2009, a la mode will ... camisoles for women who have or will undergo mastectomy, lumpectomy ... bra fitters have been trained and certified by Amoena to ... provide a safe, comfortable and supportive environment for women of ...
... Homeopathic Product Offers Clinically Proven Effective Alternative to Controversial ... popular belief, common colds do not decrease ... the availability of a new, naturally safe cold remedy, ... to combat this prevalent virus, which actually strikes more ...
... 4 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... Commercial Development of BioMarin, will present a company update at ... March 11th, 2009 at 2:30 p.m. ET. Interested parties ... via the investor section of the BioMarin website, www.BMRN.com ...
... Inc. (Nasdaq: CLRT ), a premier technology and ... announced that it has rescheduled the release of its financial ... to Wednesday, March 11th in order to complete its year ... of its Form 10-K for the year ended December 31, ...
... Calif., March 4 Scanning the CDC website can ... The CDC concedes that over two million patients will ... many as 100,000 will die as a result. CDC ... morbidity risks and add 9 additional days to a ...
Cached Medicine News:Health News:Obsessive symptoms in childhood can multiply the probabilities of an obsessive compulsive disorder 2Health News:a la mode Bra Fitting Specialty Boutique Now Has Trained Fitters and Products for Women Who Are Post Op Mastectomy or Lumpectomy 2Health News:Naturally Safe Zucol(TM) Brings Europe's Leading Cold Remedy to United States 2Health News:Naturally Safe Zucol(TM) Brings Europe's Leading Cold Remedy to United States 3Health News:Naturally Safe Zucol(TM) Brings Europe's Leading Cold Remedy to United States 4Health News:BioMarin to Present at the Barclays Capital Global Healthcare Conference 2Health News:Clarient Reschedules Fourth Quarter and Year-End 2008 Financial Results Release To Wednesday, March 11th; Conference Call and Webcast Rescheduled For 5:00 PM EDT That Day 2Health News:Mercy Hospital at Folsom Acquires Advanced Germicidal Technology to Battle MRSA, C. diff, Acinetobacter and Other Drug-Resistant Pathogens 2
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... The first mobile clinical assistant ... A convergence of technologies in the ... you normally do during your,shift such ... and take pictures using one single ...
Assay development using client's antibodies and antigens to meet diagnostic target...
Medicine Products: